SCHEMBL1423375

SCHEMBL1423375

O=Cc1ccc(=O)[nH]c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8828164 0.82 ALDH1A1 (0.40)
SCHEMBL3719326 0.78
SCHEMBL13575346 0.75 IDH1 (0.44)
SCHEMBL4277348 0.73 IDH1 (0.42)
SCHEMBL13575341 0.73 KDM4E (0.50)
SCHEMBL21459915 0.70 IDH1 (0.41)
SCHEMBL21459913 0.70 IDH1 (0.41)
SCHEMBL4956384 0.67 CYP2A6 (0.69)
SCHEMBL31171 0.67 CYP2A6 (0.69)
SCHEMBL21459324 0.67 ALDH1A1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727934-A1 TREM2 AGONISTS F. Hoffmann-La Roche AG (CH) 2026-04-22 EP disclosed
EP-3773573-B1 ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) MORPHIC THERAPEUTIC INC (US) 2026-03-18 EP disclosed
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
EP-4683666-A1 PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS ModernaTX, Inc. (US) 2026-01-28 EP disclosed
US-20260014258-A1 PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS MODERNATX, INC. (US) 2026-01-15 US disclosed
US-20250346609-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES INC (US) 2025-11-13 US disclosed
EP-4613332-A2 COT MODULATORS AND METHODS OF USE THEREOF Gilead Sciences, Inc. (US) 2025-09-10 EP disclosed
WO-2025128873-A1 HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-06-19 WO disclosed
EP-4559525-A2 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 Morphic Therapeutic, Inc. (US) 2025-05-28 EP disclosed
EP-3896064-B1 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS GILEAD SCIENCES INC (US) 2025-05-21 EP disclosed
US-5952360-A Method for treating neuropathic pain ELI LILLY AND COMPANY (US) 1999-09-14 US disclosed
US-5942530-A Method for treating pain ELI LILLY AND COMPANY (US) 1999-08-24 US disclosed
EP-0908454-A2 Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0908186-A2 Method for treating pain ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0908180-A2 Use of phenyl oxazole or phenyl thiazole derivatives for treating pain ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0906755-A2 Use of phenyl oxazole or phenyl thiazole derivatives for treating neuropathic pain ELI LILLY AND COMPANY (US) 1999-04-07 EP disclosed
WO-1999009980-A1 METHOD FOR TREATING PAIN ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed
EP-0373463-B1 Process for the preparation of 2-chloro-5-chloromethyl pyridine BAYER AG (DE) 1995-01-18 EP disclosed
US-4958025-A Preparation of 2-chloro-5-chloromethylpyridine BAYER AKTIENGESELLSCHAFT (DE) 1990-09-18 US disclosed
EP-0373463-A2 Process for the preparation of 2-chloro-5-chloromethyl pyridine BAYER AG (DE) 1990-06-20 EP disclosed